Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 11/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3766157 | 0.92 | FAAH (0.55) | FAAHEPHX2POLBTP53SMN1; SMN2 | |
| SCHEMBL3766399 | 0.85 | FAAH (0.67) | FAAHEPHX2TP53SMN1; SMN2MAPT | |
| SCHEMBL3761183 | 0.82 | FAAH (0.66) | FAAHEPHX2TP53SMN1; SMN2MAPT | |
| SCHEMBL3765495 | 0.82 | FAAH (0.69) | FAAHEPHX2 | |
| Hydrochloric Acid SCHEMBL3770663 | 0.81 | FAAH (0.68) | FAAHEPHX2 | |
| SCHEMBL3765745 | 0.80 | FAAH (0.61) | FAAHEPHX2POLBTP53 | |
| SCHEMBL3764625 | 0.78 | FAAH (0.56) | FAAHEPHX2POLBTP53MAPT | |
| SCHEMBL3641179 | 0.78 | FAAH (0.56) | FAAHEPHX2TP53SMN1; SMN2MAPT | |
| SCHEMBL3770680 | 0.78 | FAAH (0.56) | FAAHEPHX2TP53SMN1; SMN2MAPT | |
| SCHEMBL3768198 | 0.78 | FAAH (0.59) | FAAHEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2164493-A2 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | Janssen Pharmaceutica, N.V. (BE) | 2010-03-24 | — | — | EP | disclosed |
| US-20090062294-A1 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2009-03-05 | — | — | US | disclosed |
| WO-2008153752-A2 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-18 | — | — | WO | disclosed |
| EP-1813606-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062294-A1 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, GPR119 | FAAH 1/4885EPHX2 424/4885POLB 1725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.